THE EFFICACY AND SAFETY PROFILE OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION

Age-related macular degeneration is the main cause of loss of sight in the world. This review presents a current view on modern drugs used for the treatment of macular degeneration. A comparison effectiveness and safety profile of bevacizumab, ranibizumab, and pegaptanib aflibercept enables us to co...

Full description

Saved in:
Bibliographic Details
Published inBezopasnostʹ i risk farmakoterapii (Online) no. 1; pp. 12 - 17
Main Authors R. N. Alyautdin, B. K. Romanov, V. K. Lepakhin, V. A. Merculov, N. A. Mironov
Format Journal Article
LanguageRussian
Published Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products 01.05.2022
Subjects
advanced therapy, medicinal products, age-related macular degeneration, bevacizumab, ranibizumab, pegaptanib, aflibercept
Online AccessGet full text

Cover

More Information
Summary:Age-related macular degeneration is the main cause of loss of sight in the world. This review presents a current view on modern drugs used for the treatment of macular degeneration. A comparison effectiveness and safety profile of bevacizumab, ranibizumab, and pegaptanib aflibercept enables us to conclude that each of these compounds has its own advantages and disadvantages. Further study will develop rational schemes of their application.
ISSN:2312-7821
2619-1164